{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:49:09Z","timestamp":1792079349787,"version":"4.4.0"},"reference-count":30,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2873 , 494832089"],"award-info":[{"award-number":["GRK 2873 , 494832089"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The DNA\/RNA helicase Schlafen11 (SLFN11) is considered a sensitivity marker of various tumor cells for cytotoxic treatment with DNA damaging agents (DDA), such as cisplatin and PARP inhibitors (PARPi). Cells can epigenetically silence SLFN11 expression to gain chemoresistance, which can be targeted by HDAC inhibitors (HDACi). Here, we investigate the predictive value of SLFN11 expression for the response to three different PARPi in ovarian cancer cells. Furthermore, we target its epigenetic downregulation via HDACi for sensitization to cisplatin and PARPi. We show that HDAC3 plays a key role in SLFN11 silencing in W1 and W1CR ovarian cancer cells, confirmed by an HDAC3 knockdown approach. Therefore, addressing HDAC3 by novel class I HDACi DS-103 and FL-007 at non-toxic concentrations restored SLFN11 expression with various consequences for DDA treatment in W1, W1CR, and SKOV-3 cells. While DS-103 and FL-007 significantly sensitized cisplatin-resistant W1CR cells to cisplatin to the level of W1 cells, the response to various PARPi remains divergent. Whereas both HDACi induced significant sensitization in W1 and W1CR cells, and DS-103 in SKOV-3 cells for niraparib cytotoxicity, cells remain unaffected in response to olaparib and rucaparib. Both compounds were also shown to be less dependent on, or independent of, SLFN11 in different ovarian cancer cells. In sum, the first time reported functional link of HDAC3 and SLFN11 appears an attractive co-treatment opportunity of DDA with HDACi. This is particularly promising for niraparib as it has a broader approval independent of BRCA status compared to other PARPi.<\/jats:p>","DOI":"10.1021\/acschembio.6c00312","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:02:19Z","timestamp":1786993339000},"page":"2169-2178","source":"Crossref","is-referenced-by-count":0,"title":["Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis"],"prefix":"10.1021","volume":"21","author":[{"given":"Julia M.","family":"Eichhorn","sequence":"first","affiliation":[{"name":"University of Bonn , , An der Immenburg 4 , ,","place":["Bonn, Germany, 53121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Menning","sequence":"additional","affiliation":[{"name":"University of Bonn , , An der Immenburg 4 , ,","place":["Bonn, Germany, 53121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7734-124X","authenticated-orcid":true,"given":"Linda","family":"Sch\u00e4ker-H\u00fcbner","sequence":"additional","affiliation":[{"name":"University of Bonn , , An der Immenburg 4 , ,","place":["Bonn, Germany, 53121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9765-5975","authenticated-orcid":true,"given":"Finn K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"University of Bonn , , An der Immenburg 4 , ,","place":["Bonn, Germany, 53121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6535-6599","authenticated-orcid":true,"given":"Philipp","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"University of Bonn , , An der Immenburg 4 , ,","place":["Bonn, Germany, 53121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-7201","authenticated-orcid":true,"given":"Gerd","family":"Bendas","sequence":"additional","affiliation":[{"name":"University of Bonn , , An der Immenburg 4 , ,","place":["Bonn, Germany, 53121"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"1","key":"2026101511061301700_cit1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1186\/s12889-022-13861-y","article-title":"The global burden and associated factors of ovarian cancer in 1990-2019: findings from the Global Burden of Disease Study 2019","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Public Health"},{"issue":"10290","key":"2026101511061301700_cit2","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"7","key":"2026101511061301700_cit3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/bjc.2016.67","article-title":"PARP inhibitors: the race is on","volume":"114","author":"Brown","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"37","key":"2026101511061301700_cit4","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026101511061301700_cit5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"32","key":"2026101511061301700_cit6","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/s41388-024-03094-1","article-title":"Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks","volume":"43","author":"Onji","year":"2024","journal-title":"Oncogene"},{"issue":"12","key":"2026101511061301700_cit7","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41416-021-01560-1","article-title":"Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response","volume":"125","author":"Willis","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"3","key":"2026101511061301700_cit8","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.18632\/oncotarget.6413","article-title":"Epigenetic inactivation of the putative DNA\/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs","volume":"7","author":"Nogales","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2026101511061301700_cit9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"2026101511061301700_cit10","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-17-0443","article-title":"Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors","volume":"24","author":"Tang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2026101511061301700_cit11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.576391","article-title":"Recent Update of HDAC Inhibitors in Lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"Pt 3","key":"2026101511061301700_cit12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/BJ20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"Ruijter","year":"2003","journal-title":"Biochem. J."},{"issue":"8","key":"2026101511061301700_cit13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167448","article-title":"SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells","volume":"1870","author":"K\u00f6nig","year":"2024","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"issue":"9","key":"2026101511061301700_cit14","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100755","article-title":"Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors","volume":"17","author":"Sch\u00e4ker-H\u00fcbner","year":"2022","journal-title":"ChemMedChem"},{"issue":"1","key":"2026101511061301700_cit15","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2025.2598478","article-title":"Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors","volume":"41","author":"Yang","year":"2026","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"22","key":"2026101511061301700_cit16","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"2026101511061301700_cit17","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.3390\/cancers14112640","article-title":"Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use","volume":"14","author":"Abbotts","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"2026101511061301700_cit18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ygyno.2021.04.015","article-title":"Entinostat, a selective HDAC1\/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer","volume":"162","author":"Gupta","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"2026101511061301700_cit19","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1158\/1535-7163.MCT-15-0374","article-title":"Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition","volume":"14","author":"Wiegmans","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"2026101511061301700_cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107556","article-title":"Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1\/HDAC-1 inhibitors","volume":"151","author":"Wu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"2026101511061301700_cit21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"2026101511061301700_cit22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41420-025-02740-1","article-title":"Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition","volume":"11","author":"K\u00f6nig","year":"2025","journal-title":"Cell Death Discov."},{"issue":"1","key":"2026101511061301700_cit23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the Cancer Dependency Map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026101511061301700_cit24","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.csbj.2022.06.007","article-title":"Unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines","volume":"20","author":"Tibor Fekete","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"19","key":"2026101511061301700_cit25","doi-asserted-by":"publisher","first-page":"17796","DOI":"10.1021\/acs.jmedchem.4c01817","article-title":"Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells","volume":"67","author":"Kraft","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026101511061301700_cit26","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1021\/acs.jmedchem.4c02373","article-title":"Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties","volume":"68","author":"Stopper","year":"2025","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026101511061301700_cit27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044265","article-title":"Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"issue":"7353","key":"2026101511061301700_cit28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"16","key":"2026101511061301700_cit29","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.3390\/ijms20163927","article-title":"Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines","volume":"20","author":"Sterzy\u0144ska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026101511061301700_cit30","doi-asserted-by":"publisher","first-page":"31937","DOI":"10.1038\/s41598-024-83447-8","article-title":"HDAC3 inhibitors induce drug resistance by promoting IL-17 A production by T cells","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."}],"container-title":["ACS Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acschembio.6c00312","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acbcct\/article-pdf\/21\/9\/2169\/66668366\/cb-2026-00312w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acbcct\/article-pdf\/21\/9\/2169\/66668366\/cb-2026-00312w.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:29:15Z","timestamp":1792078155000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acbcct\/article\/21\/9\/2169\/5263520\/Novel-Class-I-HDAC-Inhibitors-Sensitize-Ovarian"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,17]]},"published-print":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.1021\/acschembio.6c00312","relation":{},"ISSN":["1554-8929","1554-8937"],"issn-type":[{"value":"1554-8929","type":"print"},{"value":"1554-8937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}